Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Free Cash Flow (2022 - 2025)

TriSalus Life Sciences' Free Cash Flow history spans 4 years, with the latest figure at -$2.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 58.87% year-over-year to -$2.5 million; the TTM value through Dec 2025 reached -$18.1 million, up 56.1%, while the annual FY2025 figure was -$18.1 million, 56.1% up from the prior year.
  • Free Cash Flow reached -$2.5 million in Q4 2025 per TLSIW's latest filing, up from -$3.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$425954.0 in Q1 2022 to a low of -$22.9 million in Q3 2022.
  • Average Free Cash Flow over 4 years is -$8.9 million, with a median of -$8.6 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 2367.4% in 2023, then skyrocketed 70.98% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$7.9 million in 2022, then dropped by 21.32% to -$9.5 million in 2023, then surged by 36.62% to -$6.1 million in 2024, then soared by 58.87% to -$2.5 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Free Cash Flow are -$2.5 million (Q4 2025), -$3.1 million (Q3 2025), and -$7.2 million (Q2 2025).